Terminology Service for NFDI4Health
All terms in CHEBI
| Label | Id | Description |
|---|---|---|
| 3-methylbutanoic acid [(2R,3S,6S,7R,8R)-3-[[(3-formamido-2-hydroxyphenyl)-oxomethyl]amino]-2,6-dimethyl-4,9-dioxo-8-pentyl-1,5-dioxonan-7-yl] ester | CHEBI_94060 | |
| D-idarate(2-) | CHEBI_21040 | [An idarate(2-) that is the conjugate base of D-idarate(1-).] |
| idarate(2-) | CHEBI_35385 | |
| D-idarate(1-) | CHEBI_35386 | |
| L-idarate(2-) | CHEBI_21332 | [An idarate(2-) that is the conjugate base of L-idarate(1-).] |
| D-idaric acid | CHEBI_21041 | [The D-enantiomer of idaric acid.] |
| idaric acid | CHEBI_24765 | |
| L-idaric acid | CHEBI_21333 | [The L-enantiomer of idaric acid.] |
| CHEBI_21042 | CHEBI_21042 | |
| N(4)-{alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc}-Asn residue | CHEBI_60640 | [An N(4)-glycosylated asparagine residue in which the glycan moiety is a branched nonasaccharide consisting of seven D-mannosyl residues and two N-acetylglucosamine residues, one of which at the reducing end is bonded to the asparagine N(4) atom.] |
| CHEBI_21043 | CHEBI_21043 | |
| (2S)-4-amino-2-[[2-(2,4-dihydroxyphenyl)-1-oxoethyl]amino]-4-oxobutanoic acid | CHEBI_94065 | |
| methyl 5-aminolevulinate hydrochloride | CHEBI_60641 | [The hydrochloride salt of methyl 5-aminolevulinate. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells.] |
| methyl 5-aminolevulinate | CHEBI_724125 | [The methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells.] |
| CHEBI_21044 | CHEBI_21044 | |
| 2-[3-[(3S,4R,6S,7S,8R,8aR)-6-[2-(2-hydroxyethoxy)phenyl]-1'-[2-methoxyethoxy(oxo)methyl]-1,2'-dioxo-8-[oxo-[4-(2-pyrimidinyl)-1-piperazinyl]methyl]-3,4-diphenyl-5'-spiro[4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine-7,3'-indole]yl]prop-2-ynyl]propanedioic acid dimethyl ester | CHEBI_94066 | |
| CHEBI_60642 | CHEBI_60642 | |
| CHEBI_21045 | CHEBI_21045 | |
| 2-[(6-methoxy-4-methyl-2-quinazolinyl)amino]-6-methyl-5-(3-methylbutyl)-1H-pyrimidin-4-one | CHEBI_94067 | |
| CHEBI_21046 | CHEBI_21046 |